OPR - Delayed Quote USD

JSPR Jul 2024 40.000 call (JSPR240719C00040000)

3.0000

0.0000

(0.00%)

As of April 4 at 2:22 PM EDT. Market Open.

Key Events

Loading Chart for JSPR240719C00040000

9/21 12:03 PM

DELL

Previous Close 3.0000
Open 3.0000
Bid 0.0000
Ask 2.7000
Strike 40.00
Expire Date 2024-07-19
Day's Range 3.0000 - 3.0000
Contract Range --
Volume 15
Open Interest 100

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference

Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones